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Abstract Snail2 is a marker of malignancy in epithelial
tumours; however, in sarcomas, it is not known if this
protein is present. Here we examine the expression of
Snail2 in one type of sarcoma, osteosarcoma, and explore
its relationship to tumour grade, subtype and anatomical
location in cases of long bone and cranial bone osteosar-
coma. Long bone osteosarcomas typically have a much
greater metastatic capability and a poorer prognosis. We
findthatSnail2isexpressedinthethreemainsubtypesoflong
bone osteosarcoma—osteoblastic, chondroblastic and fibro-
blastic. Regression analysis showed that Snail2 expression
wasstatisticallycorrelatedwithtumourgrade(p=0.014)inall
of these subtypes. Snail2 was only expressed in high-grade
cranial bone osteosarcomas, suggesting a link between
Snail2 expression and metastasis. This is the first time
Snail2 has been associated with any sarcoma, and this study
shows that Snail2 may be a useful prognostic marker for this
disease.
Keywords Osteosarcoma.Snail2.Runx2.Prognostic
marker
Introduction
The Snail family of transcription factors, of which there are
at least three members, are zinc finger proteins that function
as transcriptional repressors [1]. Target genes are recog-
nised by a conserved carboxy-terminal domain that binds a
hexanucleotide DNA motif (5′-CACCTG-3′) known as the
E-box [2]. The functions of Snail1 and Snail2, which was
originally named Slug, have been best characterised in the
developing embryo where they have been shown to
regulate epithelial–mesenchymal transitions (EMT).
This function of Snail family members has been most
studied in neural crest cells, where Snail2 was originally
defined as a marker of pre-migratory and migratory neural
crest [3]. It is now known that it plays a key role in the
process of EMT by downregulating E-cadherin, a cell–cell
adhesion molecule, therefore allowing the cells to break
their cell–cell contacts and become mesenchymal [4].
Interestingly, during embryonic development, Snail2 is also
expressed in some mesenchymal tissues. For example,
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DOI 10.1007/s13277-010-0146-1during long bone development in the mouse, Snail2 is
present in proliferating and hypertrophic chondrocytes and
also perichondrial/periosteal cells [5]. Since these tissues
are originally derived from mesenchyme, they do not
undergo EMT; therefore, it is likely that Snail2 also
regulates other processes. Indeed, it has recently been
suggested that Snail2 promotes differentiation of osteoblast
precursor cells [6].
It is well-known that developmental mechanisms are
recapitulated in many types of cancer. This is particularly
true for Snail2 signalling which contributes to progression
in a range of epithelial tumour types (e.g., breast, lung and
ovarian cancers) by regulating the motility and plasticity of
cells [7]. In this context, Snail2 is presumed to be a part of
the mechanism that switches the tumour cell phenotype
from epithelial to mesenchymal in the process of cell
invasion with disease progression. There is, however, a
diverse group of mesenchymally derived cancers, the
sarcomas, which originate from numerous cell types
including fibroblasts, chondroblasts and osteoblasts [8].
Since Snail2 is known to be expressed in many of these
mesenchymal tissues in the developing embryo, it is
possible that its expression may be reactivated in the
process of tumourigenesis; however, to the best of our
knowledge, there are currently no reports describing its
expression or function in mesenchymal tumours.
Osteosarcoma is one type of mesenchymal tumour and is
the most prevalent primary bone tumour [9], occurring
predominantly in the metaphyseal region of long bones in
adolescents [10]. It is a malignant tumour that often
metastasizes to other organs, with a predilection for the
lung. Although relatively rare in humans, with one to three
cases per million annually in the USA [10], it is much more
common in larger breeds of middle-aged dogs with about
8,000 cases diagnosed each year [9]. Clinically canine and
human osteosarcomas are indistinguishable with regard to
histology and gene expression, and in both cases, the
primary tumour tends to develop in the appendicular
skeleton and is associated with a high risk of metastasis to
the lungs [11]. It has therefore been proposed that these
naturally occurring canine osteosarcomas could be used as
an appropriate model for the human disease due to these
similarities in tumour biology and metastatic behaviour [12]
coupled with the easier access to clinical material.
We therefore undertook a study using archived canine
material to determine whether Snail2 is re-expressed in
osteosarcomas, of various histological grades and subtypes,
from different anatomical locations. Furthermore, to deter-
mine whether Snail2 expression is common to tumours
from other species, we also characterised Snail2 expression
in feline appendicular osteosarcomas. Our finding that
expression of Snail2 protein is common to both canine
and feline osteosarcomas and the very high genetic
similarity between canine and human osteosarcomas raises
the potential that Snail2 may also be present in human
cases.
Methods and materials
Tissue samples
The tissues used in this study were archived material from a
commercial veterinary diagnostic laboratory. All tissues
were fixed, processed and embedded in paraffin wax using
routine methods. Tissues were sectioned (4 μm) and
mounted on poly-L-lysine slides for haemotoxylin and
eosin staining and immunohistochemical analysis.
Tumour grading
Osteosarcomas were classified as described by the World
Health Organisation (WHO; [13]), being divided into
osteoblastic, fibroblastic and chondroblastic types on the
basis of the extracellular matrix produced by the neoplastic
cells. Tumours were then graded as well-differentiated,
intermediate grade and poorly differentiated using standard
WHO criteria relating to nuclear pleomorphism, cellular
atypia and mitotic index.
Immunohistochemistry
Sections were de-waxed in xylene, rehydrated in a graded
series of ethanols and then washed in distilled water (dH2O)
and phosphate-buffered saline (PBS). Endogenous peroxi-
dase activity was quenched by incubation with 3%
hydrogen peroxide in methanol for 30 min. Sections were
then pre-blocked with PBS containing 0.05% Triton X-100
and 10% calf serum (PBS/TX-100/CS) for 45 min and
incubated with primary antibody overnight at 4°C. Primary
antibodies used were rabbit anti-Snail2 (4 μg/ml; Santa
Cruz, Inc., USA), rabbit anti-Snail1 (4 μg/ml; Santa Cruz,
Inc., USA) and goat anti-Runx2 (4 μg/ml; Santa Cruz). For
negative controls, either rabbit or goat IgG was substituted
for the primary antibody. The sections were then incubated
with either rabbit or goat biotin conjugated secondary
antibody (Dako, Glostrup, Denmark) for 45 min. Detection
was carried out using the Vector ABC method with 3.3′-
diaminobenzidine tetrachloride as substrate (Vector Labs,
Peterborough, UK). After staining, sections were counter-
stained with 1% haematoxylin solution for 1 min, dehy-
drated in a series of graded ethanols, cleared with xylene
and mounted using VectaMount (Vector Labs). Sections
were viewed using a Leica DM4000B light microscope and
photographed with a DC 500 Leica digital camera (Leica,
Solms, Germany).
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Human osteosarcoma cell line TE85/HOS, rat osteosarcoma
cell line ROS 17/2.8, canine osteosarcoma cell line D-17
and human embryonic kidney cells HEK293 were seeded in
media (Dulbecco’s modified Eagle’s medium supplemented
with 10% (v/v) foetal calf serum, 2 mM L-glutamine, and
100 U/ml penicillin and 100 μg/ml streptomycin) at a
density of 5×10
4 cells onto 12-well plates and incubated at
37°C with 5% CO2 in a humidified atmosphere. When
confluent, cells were lysed for Western blotting (refer to
Supplemental Fig. 1).
Western blotting
The specificity of Snail2 antibody was verified using
Western blotting in various human, rodent and canine
osteosarcoma cell lines and in Snail2 overexpressing
HEK293 cells. Immunoblotting was performed as previ-
ously described [14]. Briefly, cells were washed in ice-
cold PBS and lysed in denaturing lysis buffer. Genomic
DNA was sheared by passage through a Qiashredder
column (Qiagen) and proteins and DNA denatured by
boiling for 5 min. Protein concentrations were determined
by the BCA assay (Perbio, Chester, UK). Ten micrograms
of protein was resolved using SDA-PAGE and electro-
transferred onto nitrocellulose membranes (Schliecher and
Schuell, Dassel, Germany). Membranes were blocked for
1 h in 5% BSA before being incubated with primary and
secondary antibodies. Proteins were visualized using the
enhanced chemiluminescence detection system (GE
Healthcare, Amersham Biosciences). Refer to Supplemental
Fig. 1.
Immunofluorescence
Sections were de-waxed, rehydrated and placed in
permeabilisation buffer (20 mM Hepes, 300 mM sucrose,
50 mM NaCl, 0.5% TX-100, 3 mM MgCl2,0 . 0 5 %
sodium azide, pH 7.0) for 15 min. Non-specific binding
was blocked by incubation with wash buffer (10% calf
serum, 0.05% sodium azide in PBS) for 1 h at room
temperature. Samples were then incubated with goat anti-
Runx2 (as described above) overnight at 4°C. Sections
were then washed with wash buffer and incubated with
Alexa Fluor® 594 donkey anti-goat IgG (Invitrogen
Molecular Probes, UK) for overnight at 4°C with rabbit
anti-Snail2 IgG followed by Alexa Fluor® 488 goat anti-
rabbit IgG (Invitrogen Molecular Probes, UK). Imaging
was performed with a Zeiss LSM 510 laser scanning
confocal microscope (Carl Zeiss, Inc., Thornwood, NY,
USA).
Fig. 1 Histological features and Snail2 expression in various canine
osteosarcoma grades. H&E (A–C) and Snail2 (D–F) in section of
osteosarcoma. High-grade (A, D), intermediate-grade (B, E) and low-
grade (C, F) tumours. Boxed area shows regions used for Snail2
localisation. A High-grade tumour showing pleomorphic cellularity
with sparse osteoid. B Intermediate-grade tumour with pleomorphic
cellularity and osteoid production. C Low-grade tumour showing
uniform cellularity and abundant osteoid production. D Intense nuclear
Snail2 localisation (arrowheads). E Moderate nuclear Snail2 localisation
(arrowheads). F Weak nuclear Snail2 localisation (arrowheads). Scale
bars=10 μm
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An ordinal logistic regression model was used to assess the
association between immunohistochemical expression and
tumour grade. Statistics presented are odds ratios (OR) and
their 95% confidence intervals (CI). Kendall’s tau-b was
presented when there is quasi-separation in the model.
Results were considered statistically significant at p<0.05,
unless otherwise specified. SPSS 17.0 for Windows was
used for all analyses.
Results
Grades of canine osteosarcoma, histological features
and Snail2 expression
Osteosarcoma cases in this study were graded from high
grade (poorly differentiated) to low grade (well differenti-
ated; Fig. 1 A–C), where high grade is associated with a
more aggressive phenotype [15]. Of the 20 cases of long
bone osteosarcoma examined, 11 were high-grade, five
were intermediate-grade and four were low-grade osteosar-
comas (Table 1). Histological examination of high-grade
osteosarcoma tissue revealed a highly cellular tumour mass
with pleomorphic neoplastic cells surrounded by sparse
areas of bony matrix (osteoid; Fig. 1 A). In contrast, low-
grade osteosarcomas had a more uniform cellular
morphology with more organised osteoid and tumour
bone (Fig. 1 C). In high-grade tumours, Snail2 expression
was prominent and largely nuclear (Fig. 1 D), compared
with intermediate- and low-grade cases where expression
decreased progressively (Fig. 1 E, F). In contrast, Snail1
had a very limited expression that did not correlate with
tumour grade (Supp. Fig 2).
Histopathological subtypes of canine osteosarcoma
and their expression of Snail2
Classically, canine osteosarcoma is characterised by the
presence of spindle-shaped cells producing osteoid [9]
(Fig. 1 B). However, several histological subtypes are
identifiable depending on the cellular differentiation and
type of matrix produced (osteoid, cartilage or fibrous tissue)
[10]. In humans, osteoblastic osteosarcomas account for
approximately 70% of cases, while chondroblastic and
fibroblastic tumours occur at roughly 10% each [16]. The
remaining 10% include telangiectatic (vascular) and giant
cell osteosarcoma. In this study, histological examination of
20 canine appendicular skeleton osteosarcomas revealed
that osteoblastic (15 cases, 75%) were most prominent,
followed by chondroblastic (three cases, 15%) and fibro-
blastic (two cases, 10%; Fig. 2 A, D, G; Table 1). In all
histopathological subtypes of high-grade osteosarcoma,
Case
no.
Age (year,
month)
Sex Breed Tumour
location
Histology
subtype
Histology
grade
1 7, 10 F Rottweiler Proximal tibia OB Intermediate
2 4, 0 F Rottweiler Proximal tibia OB High grade
3 4, 0 M Labrador Proximal tibia OB High grade
4 7, 0 M Greyhound Distal radius OB High grade
5 8, 5 M Rottweiler Proximal tibia CB High grade
6 8, 0 M WHWT Radius FB High grade
7 8, 5 M Retriever Proximal tibia OB Intermediate
8 9, 7 M SBT Radius OB High grade
9 10, 0 F Labrador Proximal tibia OB Low grade
10 1, 7 M Staffie cross Proximal tibia CB Low grade
11 1, 6 M Labrador Proximal tibia OB High grade
12 8, 0 F Weimaraner Distal femur OB High grade
13 11, 0 F Lurcher Distal femur OB High grade
14 6, 6 M Greyhound Distal radius OB Intermediate
15 9, 0 M Rottwieler Distal radius OB Intermediate
16 2, 0 F Rottwieler Proximal fibula CB High grade
17 12, 0 M Retriever Proximal humerus OB Low grade
18 2, 6 F Malamute Proximal tibia OB Intermediate
19 10, 11 F GSD Tibia FB Low grade
20 8, 0 M Labrador Proximal tibia OB High grade
Table 1 Summary of clinical
and histology data from canine
long bone osteosarcoma
OB osteoblastic, CB chondro-
blastic, FB fibroblastic
518 Tumor Biol. (2011) 32:515–526Snail2 protein was present (Fig. 2 C, F, I). The initial
observation that low-grade tumours had less Snail2 protein
also holds true for all three subtypes.
Canine osteoblastic subtype osteosarcomas express
the preosteoblast marker Runx2
Osteoblastic osteosarcomas are the most common histo-
logical subtype, and they display characteristics of
undifferentiated osteoblasts [16]. Therefore to further
demonstrate that the canine osteosarcomas in this study
had osteoblastic characteristics, we looked for expression
of Runx2, a transcriptional regulator necessary for the
commitment of mesenchymal cells into the osteoblastic
lineage [17]. This analysis showed nuclear Runx2 immu-
noreactivity in the osteoblastic subtypes (Fig. 3 B), but not
in either the fibroblastic or chondroblastic subtypes that
we examined (Fig. 3 E, F, H, I). Thus, Runx2 staining
shows that high-grade osteoblastic osteosarcomas contain
large numbers of preosteoblast-like cells.
Snail2 and Runx2 co-localise in high-grade tibial canine
osteosarcomas
Since these canine osteosarcomas expressed both Snail2
and Runx2, we assessed whether these molecules co-
localised in cells of 11 high-grade tibial osteosarcomas.
Both Snail2 and Runx2 were present in the nuclei
of cells in high-grade neoplasm (n=11/11; Fig. 4 B–D,
F–H). The mainly nuclear localisation of Snail2 therefore
suggests that it is active in the early osteoblastic cells in
these tumours [18].
Similar analysis in low-grade tumours showed barely
detectable levels of Snail2 and an absence of Runx2 (Fig. 4
J, K, L). This result suggests that Snail2 is localised in
preosteoblast-like cells in high-grade tumours.
Fig. 2 Snail2 expression in canine long bone osteosarcoma subtypes.
H&E (A, D, G) and Snail2 immunolocalisation (B, C, E, F, H, I).
Sections of high-grade osteosarcoma showing osteoblastic (A–C),
chondroblastic (D–F) and fibroblastic (G–I) subtypes. Boxed area
shows regions used for Snail2 immunolocalisation. All high-grade
osteosarcomas show Snail2 nuclear localisation (arrowheads in C, F,
and I). Scale bars=10 μm
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from cranial skeleton
Osteosarcomas of cranial bones are less common than
tumours of appendicular bones, and in canines, there is
usually a better clinical outcome with only 10% of tumours
undergoing metastasis, in comparison to osteosarcomas of
the appendicular skeleton in which 75–85% undergo
metastasis [19]. Having determined the localisation of
Snail2 protein in osteosarcomas of the appendicular
skeleton, we went on to characterise Snail2 localisation in
ten osteosarcomas from flat bones of the cranial skeleton
(see Table 2). We found intense Snail2 staining in high-
grade cranial skeletal osteosarcomas (Fig. 5 B, C), and this
co-localised with Runx2 in the nuclei of cells in these
tumours (Fig. 5 D, E).
In low-grade osteosarcomas, Snail2 was barely detect-
able and Runx2 was absent (Fig. 5 G–J). Interestingly,
Snail2 was detected in lower numbers of osteosarcoma
cases of the cranial skeleton (n=4/10) in comparison with
long bone tumours (n=20/20). This suggests that Snail2 is
expressed in a higher proportion of tumours of the
appendicular skeleton than in the cranial counterparts.
Localisation of Snail2 and Runx2 in feline appendicular
osteosarcomas
Osteosarcomas of the appendicular skeleton behave
differently in felines compared to canines where they
tend to be metastatically more aggressive [20]. We
therefore compared the cellular pattern of immunolocali-
sation of Snail2 in feline versus canine appendicular
osteosarcomas. In feline osteosarcomas (see Table 3), a
similar pattern of immunolocalisation to that seen in
canine osteosarcomas was found. Prominent Snail2 im-
munoreactivity was detected in high-grade tumours (Fig. 6
B, C) compared to barely detectable staining in the low-
grade tumours (Fig. 6 G, I). Similarly Runx2 protein was
also present in the cells of high-grade tumours (Fig. 6 D)
but absent in low-grade tumours. This proves there is a
Fig. 3 Runx2 expression in canine long bone osteosarcoma subtypes.
H&E (A, D, G) and Runx2 immunolocalisation (B, C, E, F, H, I).
Sections of high-grade osteosarcoma showing osteoblastic (A–C),
chondroblastic (D–F) and fibroblastic (G–I) subtypes. Boxed area
shows regions used for Runx2 immunolocalisation. Only osteoblastic
osteosarcomas show positive immunoreactivity (arrowheads in C).
Scale bar=10 μm
520 Tumor Biol. (2011) 32:515–526consistent correlation between grade and Snail2 in more than
one species. However, it also suggests that nuclear Snail2 is
not a good correlate for metastasis in cats at least, as the
overall incidence of this complication in this species is low.
Correlation between expression of Snail2 and tumour grade
The intensity of Snail2 immunostaining was scored based
on four levels: negative (0), weakly (1), moderately (2) or
strongly positive (3). A second score was employed for
evaluating the extent of Snail2 expression. This was based
on a three-point scale for distribution, with slides being
scored as 0–15% (1), 16–30% (2) and >30% (3) of cells
stained. For each sample, a cumulative score was also
generated by multiplying the intensity and distribution
scores for Snail2 staining. This serves to expand the
number of possible scores for any given tumour. Data have
been summarized in Table 4. To determine whether any of
Fig. 4 Co-localization of Snail2 and Runx2 in a high-grade tibial
osteosarcomas. H&E stain (A, E, I), immunolocalisation of Snail2 (B,
F, J), Runx 2 (C, G, K) and co-localization (D, H, L). High-grade
tumours are shown (A–H) and low-grade tumour (I–L). Boxed area
shows regions used for Snail2 and Runx2 co-localization. In high-
grade tumours, Snail2 and Runx2 co-localise (arrowheads in D and
H). Arrowheads indicate the same cells expressing both proteins.
Inserts in B–D are ×100 magnification. Scale bar=10 μm
Case no. Age Sex Breed Tumour Histology Histology
1 14, 0 M Bull terrier Mandible FB High grade
2 10, 6 F Lurcher Premolar tooth OB Low grade
3 10, 0 M GSD Mandible CB Low grade
4 8, 0 M Pointer Mandible OB Intermediate
5 13, 9 M Retriever Oral cavity OB Low grade
6 12, 0 M Chow cross Oral gingiva OB Intermediate
7 15, 11 M Retriever Oral mass OB Low grade
8 14, 0 F SBT Mandible OB High grade
9 10, 0 F Spaniel Oral mucosa OB High grade
10 9, 0 F Labrador Oral mass OB High grade
Table 2 Summary of clinical
and histology data from canine
cranial osteosarcoma
OB osteoblastic, CB chondro-
blastic, FB fibroblastic
Tumor Biol. (2011) 32:515–526 521these scores could be used as a prognostic indicator of
severity, we tested the correlation between tumour grade
and each score. This showed that both increased intensity
for Snail2 and cumulative score are associated with severity
of tumour (OR=11.39, 95% CI 1.62–80.0, p=0.014; OR=
2.57, 95% CI 1.16–5.69, p=0.020, respectively). However,
distribution scores for Snail2 showed no statistically
significant correlation with different tumour grade catego-
ries (OR=3.94, 95% CI 0.85–18.2, p=0.08). We also
examined the association between tumour grade and Snail2
intensity in canine cranial and feline appendicular osteo-
sarcomas (Tables5 and 6). However, there was no significant
association between tumour grade and Snail2 intensity in
cranial osteosarcoma (p=0.26; see supplementary Table 2).
An ordinal logistic regression was fitted for the feline data
set; however, the algorithm failed to converge due to quasi-
complete separation as a result of the small group sizes (See
supplementary Table 3). When Snail2 intensity increases the
tumour grade also increases (Kendall tau-b=0.757,p<0.001;
see Table 6).
Discussion
Osteosarcomas are aggressive tumours that show a wide
range of histological variants and cellular differentiation
states. In canines and also humans, approximately 77% of
osteosarcomas occur in the appendicular skeleton [12]. The
site of origin of a tumour is an important factor that largely
determines its characteristics. Typically tumours originating
in the appendicular skeleton demonstrate a much more
aggressive behaviour than those from other sites [19].
Advances in clinical management of osteosarcoma have
been made; however, our understanding of the molecular
pathogenesis of this disease is still rather limited. To date,
there have been a limited number of prognostic markers
identified that could be used in the clinic to identify patients
with either a favourable or poor prognosis.
Two molecules that have been linked to metastasis in
osteosarcoma are c-met and ezrin. C-met, the receptor for
the hepatocyte growth factor, was found to be upregulated
in primary canine osteosarcomas (including metastases)
Fig. 5 Co-localization of Snail2 and Runx2 in a high-grade cranial
osteosarcoma. H&E stain (A, F), immunolocalisation of Snail2 (B, C,
G, H), Runx 2 (D, I) and co-localization (E, J). High-grade (A–E) and
low-grade (F–J) tumours shown. In high-grade tumours, Snail2 and
Runx2 co-localise (arrows in E). Arrows in C and D indicate the same
cells express both proteins. Low-grade tumours express little Snail2 or
Runx2. Boxed area shows regions used for Snail2 and Runx2 co-
localization. Scale bars=10 μm
Case no. Age (year, month) Sex Breed Tumour
location
Histology
subtype
Histology
grade
1 9, 4 M DLH Femur OB Intermediate
2 3, 0 M DSH Proximal tibia OB High grade
3 F DLH Stifle OB Low grade
4 12, 0 F DSH Femur FB High grade
5 12, 0 F DLH Distal femur FB High grade
6 8, 0 M DSH Distal femur CB High grade
7 14, 0 M DSH Humerus OB Low grade
8 12, 0 F DSH Tibia OB High grade
9 9, 6 F DSH Femur FB High grade
10 11, 7 M DLH Femur OB Intermediate
Table 3 Summary of clinical
and histology data from feline
long bone osteosarcoma
OB osteoblastic, CB chondro-
blastic, FB fibroblastic
522 Tumor Biol. (2011) 32:515–526[21], and inhibition of its function was able to limit invasion
of canine osteosarcoma cells [22]. Ezrin, a cytoskeletal linker
protein of the ERM family, has also been found in both
canine and human osteosarcoma [23, 24] and to be correlated
with metastasis and poor clinical outcome.
There are, however, other genes that may be indicative
of a more malignant phenotype, for example, pRB, p53 and
t h ep r o t o - o n c o g e n ec - f o s[ 25] that are expressed in
osteosarcoma. To date, mouse models of osteosarcoma
have been developed, for example, pRb and p53 inactiva-
tion or c-fos activation, to aid in the study of osteosarcoma
biology. These models do indeed produce tumours that
contain neoplastic bone; however, it is unlikely that any of
them truly recapitulates the human disease. They were all
Fig. 6 Co-localization of Snail2 and Runx2 in a high-grade feline
long bone osteosarcoma. H&E stain (A, F), immunolocalisation of
Snail2 (B, C, G, H), Runx 2 (D, I) and co-localization (E, J). High-
grade (A–E) and low-grade (F–J) tumours shown. Arrows in C and D
indicate the same cells express both proteins. Low-grade tumours
express little Snail2 or Runx2. Boxed area shows regions used for
Snail2 and Runx2 co-localization. Scale bar=10 μm
Case no. Tumour grade Snail2 staining
intensity
Distribution of staining Cumulative score
01 2 3 1 ( 0 –15%), 2 (16–30%),
3 (>30%)
Intensity ×
distribution
2 High grade ✓ 26
3 High grade ✓ 39
4 High grade ✓ 24
5 High grade ✓ 39
6 High grade ✓ 24
8 High grade ✓ 12
11 High grade ✓ 24
12 High grade ✓ 11
13 High grade ✓ 36
16 High grade ✓ 24
20 High grade ✓ 24
1 Intermediate ✓ 22
7 Intermediate ✓ 12
14 Intermediate ✓ 24
15 Intermediate ✓ 24
18 Intermediate ✓ 11
9 Low grade ✓ 22
10 Low grade ✓ 11
17 Low grade ✓ 12
19 Low grade ✓ 22
Table 4 Relationship between
Snail2 expression and tumour
grade in canine long bone
osteosarcoma
Tumor Biol. (2011) 32:515–526 523derived by a monogenetic event and thus may not
sufficiently represent the heterogeneity of osteosarcoma.
These models therefore may be inappropriate for studying
the biology of these tumours and more importantly for
testing therapies designed for human osteosarcoma. The
similarity between canine and human osteosarcoma, cou-
pled with the relatively higher number of canine cases, may
make this a more apt model for studying osteosarcoma
biology and the design and testing of therapies for human
osteosarcoma.
In this study, we describe the expression of the
transcription factor Snail2 in spontaneously occurring
models of osteosarcoma, the first time this protein has
been identified in this type of tumour in any species.
Furthermore, we showed by immunohistochemistry that
there was a positive correlation between levels of Snail2
expression and grade of tumour, suggesting that Snail2
could be another predictor of clinical outcome in cases of
osteosarcoma.
In epithelial tumours, Snail2 is an established marker of
malignancy contributing to both the onset and progression
of the disease [7]. The best characterised function of Snail2
in epithelial tumours is its ability to promote EMT, which is
achieved in part by directly downregulating the cellular
adhesion molecule E-cadherin and thus promoting cell
migration [1].
Since osteosarcomas are tumours of mesenchymal origin
[9], there is no need for cells to undergo EMT; therefore,
Snail2 must be regulating other processes in this tumour type.
However, the precise role that Snail2 plays in these
mesenchymal tumours is yet to be defined. During embryonic
development, Snail2 is expressed in some mesenchymally
derived cells, for example, in proliferating chondrocytes and
osteoblast precursors in endochondral bone [5].
SomeofthefunctionsofSnail2inosteoblastshaverecently
been identified. In this instance, Snail2 has been shown to
bind to the promoter of Runx2 and promote transcription [6].
Since Runx2 is a key regulator of the commitment of
Case no. Tumour grade Snail2 staining
intensity
Distribution of staining Cumulative score
012 31 ( 0 –15%), 2 (16–30%),
3 (>30%)
Intensity ×
distribution
1 High grade ✓ 26
8 High grade ✓ 10
9 High grade ✓ 22
10 High grade ✓ 10
4 Intermediate ✓ 24
6 Intermediate ✓ 11
2 Low grade ✓ 10
3 Low grade ✓ 10
5 Low grade ✓ 10
7 Low grade ✓ 10
Table 5 Relationship between
Snail2 expression and tumour
grade in canine cranial
osteosarcoma
Case no. Tumour grade Snail2 staining
intensity
Distribution of staining Cumulative score
01231 ( 0 –25%), 2 (26–50%),
3 (>50%)
Intensity ×
distribution
2 High grade ✓ 26
4 High grade ✓ 12
5 High grade ✓ 13
6 High grade ✓ 26
8 High grade ✓ 11
9 High grade ✓ 12
1 Intermediate ✓ 11
10 Intermediate ✓ 10
3 Low grade ✓ 10
7 Low grade ✓ 10
Table 6 Relationship between
Snail2 expression and tumour
grade in feline long bone
osteosarcoma
524 Tumor Biol. (2011) 32:515–526mesenchymal cells to the osteoblastic lineage [26], Snail2
therefore promotes osteoblastic differentiation. It should be
noted this is in marked contrast to the relationship between
Snail1 and Runx2, where Snail1 represses Runx2 and there
is an inverse correlation in their expression [17]. This
suggests that Snail2 and Snail1 have opposing roles in
osteoblast differentiation. This is a rare departure from the
norm, where Snail1 and Snail2 have similar or additive
functions, and suggests that Snail transcription factors can
have more complex roles than previously thought.
In our study, both Snail2 and Runx2 were present in
osteoblastic osteosarcoma subtypes and in many cases were
co-expressed. This therefore suggests that increased Snail2
expression upregulates Runx2 in osteoblastic osteosarcomas.
The presence of Runx2 in these tumours shows that they
contain cells with the characteristics of osteoblastic progenitor
cells. This is in agreement with other studies where osteosar-
comas were shown to contain cells that have become trapped in
theearlystagesofdifferentiationandthattheyremainrefractory
to osteogenic stimuli[27]. It could therefore be that maintained
Snail2 and Runx2 expression results in an inability of these
cells to differentiate fully, trapping them in preosteoblastic
proliferative phenotype. Alternatively, it may be that Snail2
and Runx2 are expressed purely as a consequence of cells
remaining in a preosteoblastic state (see Fig. 7). While we did
not find an association between Snail2 and Runx2 in
chondroblastic or fibroblastic osteosarcomas, we note that
the numbers of these tumours examined were low.
It may be possible that Snail2 has other functions in
osteosarcoma. One such function could be to decrease cell–
cell adhesion and therefore promote cellular migration
producing a more aggressive tumour. Indeed, in canine
appendicular long bone tumours, which we have shown to
have high levels of Snail2, metastasis occurs in 80–90% of
cases. We therefore went on examine Snail2 in canine
osteosarcomas of the skull, which are rarer and have a
lower frequency of metastasis [19]. In these cases, it was
evident that Snail2 expression was present in much lower
proportion of cases. This implies that Snail 2 could be
involved in regulating cell migration. Alternatively, the
different rates of metastasis may be purely due to the
different origins of these tumours. It may be that neural
crest-derived cells that give rise to cranial tumours are
inherently less able to metastasize.
Fig. 7 A model for Snail2 and Runx2 activity in development of
osteosarcoma. Upper panel: a diagrammatic representation of the
function of Snail2 and Runx2 during normal bone differentiation.
Snail2 promotes Runx2 expression and the progression of osteopro-
genitors to pre-osteoblasts. Lower panel: a model for the function of
Snail2 and Runx2 in osteosarcoma. The increased levels of Snail2
keep Runx2 expression equally high. This prevents progression of
cells to subsequent early and mature osteoblast states
Tumor Biol. (2011) 32:515–526 525To further investigate whether Snail2 expression could be
linked with metastasis, we analysed a series of feline
osteosarcomas from appendicular long bone. In these cases,
metastasis is known to occur in approximately 5–10% of
animals compared with 80–90% in canines [20]. We would
therefore expect lower levels of Snail2 in these cases if it is a
regulator of metastasis. Our data show that in some of the
feline cases, high levels of Snail2 were present and therefore
Snail2 may not be associated with metastasis in felines. This
study is, however, limited by the lack of clinical follow-up
information, and we do not know whether the individual
feline cases with high levels of Snail2 developed metastases
in the future. It could therefore be possible that Snail2
promotes metastasis in felines; however, we currently lack
the clinical data to investigate this. Further analysis of the
role of Snail2 and Runx2 in cell–cell adhesion and in
promoting cellular migration of osteosarcoma cells in other
species including humans would allow us to confirm
association of Snail2 with metastasis. Alternatively, there
may be other explanations for why canine osteosarcomas are
more metastatic than those in felines. We know that tumour
development and metastasis are multifactorial events; there-
fore, it may be that in canines these tumours are genetically
more prone to the events that induce metastasis and
expression of Snail2 is a single event along this pathway.
In conclusion, Snail2 is statistically correlated with tumour
severity in appendicular canine osteosarcomas. Since canine
and human osteosarcomas are genetically very similar, this
raises the possibility that Snail2 could be used as a prognostic
marker in cases of human appendicular osteosarcoma.
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